Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 12, 2026
Novo Nordisk has announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) seeking approval for etavopivat, an investigational once-daily oral therapy for adolescents and adults living with sickle cell disease (SCD). The submissions include a New Drug Application (NDA) to the FDA and a Marketing Authorisation Application (MAA) to the EMA. The applications are supported by findings from the Phase 3 HIBISCUS clinical trial, which evaluated the efficacy and safety of etavopivat in people aged 12 years and older with sickle cell disease. If approved, the investigational medicine could offer a new disease-modifying treatment approach for patients affected by this inherited blood disorder. Sickle cell disease remains a significant global healthcare challenge, affecting approximately 8 million people worldwide, including around 100,000 individuals in the United States, 110,000 in Europe and 1.28 million in India. The disease is associated with recurrent painful episodes, chronic anaemia and potentially life-threatening complications. Novo Nordisk believes etavopivat could address important unmet medical needs by targeting the underlying biological mechanisms responsible for red blood cell sickling.
Phase 3 HIBISCUS Trial Supports Regulatory Submissions
The FDA and EMA submissions are based on findings from the HIBISCUS Phase 3 clinical development programme, which investigated the efficacy and safety of etavopivat compared with placebo in adolescents and adults living with sickle cell disease. The pivotal HIBISCUS study was designed to evaluate two important clinical outcomes: the annualised rate of vaso-occlusive crises (VOCs) at Week 52 and the proportion of patients achieving a haemoglobin response of greater than 1 g/dL at Week 24. Participants were also permitted to continue receiving standard-of-care treatments throughout the study, allowing researchers to evaluate etavopivat alongside existing disease management approaches. According to topline results announced by Novo Nordisk in April 2026, etavopivat demonstrated a 27% reduction in vaso-occlusive crises compared with placebo, together with an approximately four-month delay in the time to the first vaso-occlusive crisis. These findings highlight the potential of the investigational treatment to reduce the frequency of painful disease episodes. Novo Nordisk has stated that more detailed findings from the Phase 3 HIBISCUS trial will be presented at a future scientific conference and published in a peer-reviewed journal. The regulatory applications represent an important milestone in the clinical development programme and move etavopivat closer to potential regulatory review in the United States and Europe.
Etavopivat Targets Red Blood Cell Metabolism
Etavopivat is an investigational, once-daily, orally available selective activator of the pyruvate kinase red blood cell isozyme (PKR), an enzyme involved in glycolysis and cellular energy production. The treatment is designed to address important biological processes associated with sickle cell disease by reducing levels of 2,3-diphosphoglycerate (2,3-DPG) and increasing the production of adenosine triphosphate (ATP) in red blood cells. Lower 2,3-DPG levels can improve haemoglobin’s affinity for oxygen, potentially reducing the polymerisation of sickle haemoglobin that contributes to the characteristic sickling of red blood cells. Increased ATP production may also help preserve red blood cell membrane integrity and flexibility, supporting improved cell survival. Through these complementary mechanisms, etavopivat is being investigated for its potential to reduce vaso-occlusive events and improve haemoglobin levels. The FDA has previously granted the investigational therapy Fast Track, Orphan Drug and Rare Pediatric Disease designations, while the European Commission has also granted it Orphan Drug designation following a positive opinion from the EMA’s Committee for Orphan Medicinal Products. These designations recognise the importance of developing potential treatment options for serious conditions with significant unmet medical needs, although they do not constitute marketing approval.
Global Development Programme and Regulatory Outlook
Novo Nordisk is continuing to evaluate etavopivat through a broader clinical development programme designed to establish its long-term safety and therapeutic potential. The programme includes HIBISCUS 2, a Phase 3b study expected to enrol approximately 510 participants aged 12 years and older, comparing once-daily etavopivat with placebo over 52 weeks. The company is also conducting the FLORAL open-label extension study to collect additional long-term safety information from participants who have completed etavopivat clinical trials. The FDA is expected to take action on the submitted NDA in 2027, while the EMA is also expected to complete its assessment of the marketing authorisation application in 2027. If regulatory approval is granted, etavopivat could expand the available treatment landscape for people living with sickle cell disease. Novo Nordisk acquired the investigational therapy through its 2022 acquisition of Forma Therapeutics, strengthening its development portfolio in rare blood disorders. The latest submissions demonstrate the company’s continued investment in innovative therapies and its commitment to addressing unmet medical needs through clinical research. The regulatory review and additional clinical evidence will determine the next steps in bringing this investigational treatment to patients.
Source: Novo Nordisk press release



